Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
Tocilizumab Promising for sJIA
Meeting Abstracts
Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.
Rheumatology Research Foundation
The Foundation is the largest private funding source for rheumatology research and training in the U.S.
ACR Convergence
Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.